Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2007 | Clinical Investigation

Enolase autoantibodies and retinal function in multiple sclerosis patients

Authors: Farzin Forooghian, Grazyna Adamus, Melanie Sproule, Carol Westall, Paul O’Connor

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2007

Abstract

Background

Electroretinographic (ERG) abnormalities have been reported in multiple sclerosis (MS), as well as the presence of circulating antiretinal antibodies. We and others have reported cases of impaired vision and diminished ERGs in MS patients with α-enolase autoantibodies. Anti-enolase antibodies have been implicated in autoimmune retinopathy. We performed this study to further explore the relationship between antiretinal antibodies and ERG changes in patients with MS.

Methods

Patients with clinically definite MS and normal visual acuity were recruited for this study, along with healthy controls. All patients and controls had ERG testing done according to ISCEV standards. Patient and control sera were analyzed for the presence of antiretinal antibodies using Western blot and ELISA techniques, and HLA class II typing was performed using polymerase chain reaction.

Results

We found a statistically significant difference between MS patients and controls in the rod-cone b-wave implicit time (p < 0.005). We found autoantibodies against α-enolase in 38% of MS patients and 11% of controls (p < 0.02). There was no statistically significant difference between ERG parameters of MS patients with α-enolase autoantibodies compared to those without α-enolase antibodies. Furthermore, the presence of α-enolase did not associate with a particular HLA haplotype.

Conclusions

Factors affecting the retina other than α-enolase antibodies may account for the delayed rod-cone b-wave implicit times observed in MS patients in this study. Anti-enolase antibodies are likely an epiphenomenon of autoimmune disease, and are not causing retinopathy in MS patients with normal visual acuity. However, the possibility of rare cases of patients with pathogenic α-enolase autoantibodies can not be excluded. The pathogenic contribution of these antibodies in MS patients with visual impairment deserves further investigation.

Keltner JL, Roth AM, Chang RS (1983) Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol 101(4):564–569PubMed

Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF (1976) Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 81(5):606–613PubMed

Harmon JP, Purvin VA, Guy J, Aptsiauri N, Sutton GP (1999) Cancer-associated retinopathy in a patient with advanced epithelial ovarian carcinoma. Gynecol Oncol 73(3):430–432PubMedCrossRef

Adamus G, Aptsiauri N, Guy J, Heckenlively J, Flannery J, Hargrave PA (1996) The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 78(2):120–129PubMedCrossRef

Adamus G (2003) Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2(2):63–68PubMedCrossRef

Weleber RG, Watzke RC, Shults WT, Trzupek KM, Heckenlively JR, Egan RA et al (2005) Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 139(5):780–794PubMedCrossRef

Whitcup SM, Vistica BP, Milam AH, Nussenblatt RB, Gery I (1998) Recoverin-associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol 126(2):230–237PubMedCrossRef

Mizener JB, Kimura AE, Adamus G, Thirkill CE, Goeken JA, Kardon RH (1997) Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol 123(5):607–618PubMed

Peek R, Verbraak F, Coevoet HM, Kijlstra A (1998) Muller cell-specific autoantibodies in a patient with progressive loss of vision. Invest Ophthalmol Vis Sci 39(10):1976–1979PubMed

10.

Biousse V, Trichet C, Bloch-Michel E, Roullet E (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1):179–181PubMed

11.

Wagemans MA, Breebaart AC (1992) Association between intermediate uveitis and multiple sclerosis. Dev Ophthalmol 23:99–105PubMed

12.

Graham EM, Francis DA, Sanders MD, Rudge P (1989) Ocular inflammatory changes in established multiple sclerosis. J Neurol Neurosurg Psychiatry 52(12):1360–1363PubMedCrossRef

13.

Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF, Pierce K (1997) The association of HLA-DR15 and intermediate uveitis. Am J Ophthalmol 123(1):70–75PubMed

14.

Raja SC, Jabs DA, Dunn JP, Fekrat S, Machan CH, Marsh MJ et al (1999) Pars planitis: clinical features and class II HLA associations. Ophthalmology 106(3):594–599PubMedCrossRef

15.

Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H et al (1997) Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 120(Pt 8):1437–1445PubMedCrossRef

16.

Kojima K, Berger T, Lassmann H, Hinze-Selch D, Zhang Y, Gehrmann J et al (1994) Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med 180(3):817–829PubMedCrossRef

17.

Berger T, Weerth S, Kojima K, Linington C, Wekerle H, Lassmann H (1997) Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 76(3):355–364PubMed

18.

Shikishima K, Lee WR, Behan WM, Foulds WS (1993) Uveitis and retinal vasculitis in acute experimental allergic encephalomyelitis in the Lewis rat: an ultrastructural study. Exp Eye Res 56(2):167–175PubMedCrossRef

19.

Ohguro H, Chiba S, Igarashi Y, Matsumoto H, Akino T, Palczewski K (1993) Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients. Proc Natl Acad Sci USA 90(8):3241–3245PubMedCrossRef

20.

Caspi RR, Sun B, Agarwal RK, Silver PB, Rizzo LV, Chan CC et al (1997) T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye 11(Pt 2):209–212PubMed

21.

Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21(2–3):197–208PubMedCrossRef

22.

Becker MD, Adamus G, Davey MP, Rosenbaum JT (2000) The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm 8(2):93–100PubMedCrossRef

23.

Guy J, Aptsiauri N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117(4):471–477PubMed

24.

Goldstein SM, Syed NA, Milam AH, Maguire AM, Lawton TJ, Nichols CW (1999) Cancer-associated retinopathy. Arch Ophthalmol 117(12):1641–1645PubMed

25.

Adamus G, Machnicki M, Seigel GM (1997) Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci 38(2):283–291PubMed

26.

Adamus G, Machnicki M, Elerding H, Sugden B, Blocker YS, Fox DA (1998) Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun 11(5):523–533PubMedCrossRef

27.

Adamus G, Amundson D, Seigel GM, Machnicki M (1998) Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun 11(6):671–677PubMedCrossRef

28.

Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I (1999) Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40(13):3160–3167PubMed

29.

Ren G, Adamus G (2004) Cellular targets of anti-alpha-enolase autoantibodies of patients with autoimmune retinopathy. J Autoimmun 23(2):161–167PubMedCrossRef

30.

Shiraga S, Adamus G (2002) Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 132(1–2):72–82PubMedCrossRef

31.

Maeda T, Maeda A, Maruyama I, Ogawa KI, Kuroki Y, Sahara H et al (2001) Mechanisms of photoreceptor cell death in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 42(3):705–712PubMed

32.

Younge BR (1976) Fluorescein angiography and retinal venous sheathing in multiple sclerosis. Can J Ophthalmol 11(1):31–36PubMed

33.

Tola MR, Granieri E, Casetta I, Monari P, Scorrano R, Mazzeo V, et al (1993) Retinal periphlebitis in multiple sclerosis: a marker of disease activity? Eur Neurol 33(2):93–96PubMed

34.

Engell T, Krogsaa B, Lund-Andersen H (1986) Breakdown of the blood-retinal barrier in multiple sclerosis measured by vitreous fluorophotometry. Acta Ophthalmol (Copenh) 64(5):583–587CrossRef

35.

Forooghian F, Kertes PJ, Aptsiauri N (2003) Probable autoimmune retinopathy in a patient with multiple sclerosis. Can J Ophthalmol 38(7):593–597PubMed

36.

Gorczyca WA, Ejma M, Witkowska D, Misiuk-Hojlo M, Kuropatwa M, Mulak M et al (2004) Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 36(2):120–123PubMedCrossRef

37.

Hood DC, Birch DG (1996) Assessing abnormal rod photoreceptor activity with the a-wave of the electroretinogram: applications and methods. Doc Ophthalmol 92(4):253–267PubMedCrossRef

38.

Maruyama I, Ohguro H, Ikeda Y (2000) Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Invest Ophthalmol Vis Sci 41(7):1657–1665PubMed

39.

Riggs LA (1986) Electroretinography. Vision Res 26(9):1443–1459PubMedCrossRef

40.

Coupland SG, Kirkham TH (1982) Flash electroretinogram abnormalities in patients with clinically definite multiple sclerosis. Can J Neurol Sci 9(3):325–330PubMed

41.

Pierelli F, Pozzessere G, Stefano E, Martelli M, Rizzo PA, Morocutti C (1985) Pattern visual evoked potentials and flash electroretinogram in clinically definite multiple sclerosis. Eur Neurol 24(5):324–329PubMed

42.

Papakostopoulos D, Fotiou F, Hart JC, Banerji NK (1989) The electroretinogram in multiple sclerosis and demyelinating optic neuritis. Electroencephalogr Clin Neurophysiol 74(1):1–10PubMedCrossRef

43.

Maruyama I, Maeda T, Okisaka S, Mizukawa A, Nakazawa M, Ohguro H (2002) Autoantibody against neuron-specific enolase found in glaucoma patients causes retinal dysfunction in vivo. Jpn J Ophthalmol 46(1):1–12PubMedCrossRef

44.

Ikeda H, Tremain KE, Sanders MD (1978) Neurophysiological investigation in optic nerve disease: combined assessment of the visual evoked response and electroretinogram. Br J Ophthalmol 62(4):227–239PubMed

45.

Li B, Barnes GE, Holt WF (2005) The decline of the photopic negative response (PhNR) in the rat after optic nerve transection. Doc Ophthalmol 111(1):23–31PubMedCrossRef

46.

Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bombardieri S, Migliorini P (2000) Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol 27(1):109–115PubMed

47.

Gitlits VM, Toh BH, Sentry JW (2001) Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase. J Investig Med 49(2):138–145PubMed

48.

Pancholi V (2001) Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58(7):902–920PubMedCrossRef

49.

Moscato S, Pratesi F, Sabbatini A, Chimenti D, Scavuzzo M, Passatino R et al (2000) Surface expression of a glycolytic enzyme, alpha-enolase, recognized by autoantibodies in connective tissue disorders. Eur J Immunol 30(12):3575–3584PubMedCrossRef

50.

Migliorini P, Pratesi F, Bongiorni F, Moscato S, Scavuzzo M, Bombardieri S (2002) The targets of nephritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev 1(3):168–173PubMedCrossRef

51.

Grigoriadis N, Ben-Hur T, Karussis D, Milonas I (2004) Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clin Neurol Neurosurg 106(3):211–217PubMedCrossRef

52.

Chitnis T, Imitola J, Khoury SJ (2005) Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord 5(1):11–26PubMedCrossRef

53.

Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 16(3):259–265PubMedCrossRef

54.

Teunissen CE, Dijkstra C, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4(1):32–41PubMedCrossRef

55.

Zaffaroni M (2003) Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci 24(Suppl 5):S279–S282PubMedCrossRef

56.

Deloulme JC, Helies A, Ledig M, Lucas M, Sensenbrenner M (1997) A comparative study of the distribution of alpha- and gamma-enolase subunits in cultured rat neural cells and fibroblasts. Int J Dev Neurosci 15(2):183–194PubMedCrossRef

57.

Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA et al (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137(1):77–83PubMedCrossRef

Title: Enolase autoantibodies and retinal function in multiple sclerosis patients
Authors: Farzin Forooghian
Grazyna Adamus
Melanie Sproule
Carol Westall
Paul O’Connor
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-006-0527-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Enolase autoantibodies and retinal function in multiple sclerosis patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2007

Successful treatment of a large choroidal abscess in an immunocompetent child

Mietz H, Krieglstein GK: Postoperative application of mitomycin C improves the complete success rate of primary trabeculectomy: a prospective, randomized trial. Graefes Arch Clin Exp Ophthalmol 2006;244:1429–1436

Oculoplastic surgery atlas eds. Nesi, Goldberg, Lemke et al.

Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases

Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study

Structural alterations of the erythrocyte membrane proteins in diabetic retinopathy